Mercury Laboratories Ltd. benchmarking: Perfomance to industry peers

Financial

	Mercury Laboratories	Concord Drugs	Curis Lifesciences
Operational Metrics
Financials
5 yr Average ROE	10.51 %	2.78 %	63.11 %
5yr average Equity Multiplier	1.49	1.87	1.91
5yr Average Asset Turnover Ratio	1.05	0.84	1.07
5yr Avg Net Profit Margin	6.6 %	1.59 %	8.37 %
Price to Book	1.78	2.82	5.79
P/E	20.22	168.14	15.47
5yr Avg Cash Conversion Cycle	-4.69 Days	233.27 Days	45.79 Days
Inventory Days	32.68 Days	152.22 Days	77.61 Days
Days Receivable	115.65 Days	106.22 Days	65.45 Days
Days Payable	157.73 Days	74.71 Days	245.93 Days
5yr Average Interest Coverage Ratio	15.15	1.69	5.43
5yr Avg ROCE	13.49 %	8.41 %	36.41 %
5yr Avg Operating Profit Margin	11.74 %	9.1 %	16.92 %
5 yr average Debt to Equity	0.13	0.55	0.12
5yr CAGR Net Profit	-10.08 %	-26.55 %	65.64 %
5yr Average Return on Assets	7.02 %	1.46 %	9.21 %
Shareholdings
Promoter Holding	73.66 %	54.39 %	n/a
Share Pledged by Promoters	0.0	0.0	n/a
Change in Promoter Holding (3 Yrs)	0.0	5.39 %	n/a
Change in Mutual Fund Holding (3 Yrs)	0.0	0.0	n/a

	Mercury Laboratories	Concord Drugs	Curis Lifesciences
Product Wise Break-Up	Product Wise Break-Up Sterile Ophthalmic Ointment 0 Oral Liquid 0 0 Capsules 0 Tablet 0 Others 100	Product Wise Break-Up Tablet 0 0 Oral Liquid 0 Sterile Ophthalmic Ointment 0 Capsules 0 Others 100	Product Wise Break-Up Tablet 87.9 External Preparation (Cream/Gel/Ointment) 4.18 Oral Liquid 4.59 Sterile Ophthalmic Ointment 0.12 Capsules 2.23 Others 0.98